HIV comorbidities and complications

A5426 Improving Physical Ability and Cellular Senescence Elimination in HIV

This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib…

Open and enrolling

The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects.

See locations

ACTG LAUNCHES IPACE-HIV TO STUDY FRAILTY INTERVENTION

ACTG is excited to undertake the first carefully controlled study evaluating senolytics as a potential intervention against frailty among people…

Jan 13, 2026

ACTG PRESENTS SLIM LIVER FINDINGS AT AASLD LIVER MEETING DEMONSTRATING IMPROVEMENTS IN BIOMARKERS OF CARDIOVASCULAR RISK AMONG PEOPLE LIVING WITH HIV AND MASLD WHO RECEIVE SEMAGLUTIDE

Nov 10, 2025

ACTG PRESENTS STUDY AT CROI DEMONSTRATING INCREASED RISK OF OBESITY AND CARDIOMETABOLIC DISEASE AFTER SWITCH TO INTEGRASE INHIBITOR-CONTAINING REGIMEN

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to…

Mar 17, 2025

ACTG PRESENTS IMPORTANT FINDINGS FROM REPRIEVE AT CROI 2025

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented findings from the REPRIEVE trial…

Mar 17, 2025

ACTG PRESENTS STUDY AT CROI DEMONSTRATING POTENTIAL OF CMV-SPECIFIC ANTIVIRAL INHIBITOR TO IMPROVE AGING-RELATED OUTCOMES AMONG PEOPLE LIVING WITH HIV AND CMV (CYTOMEGALOVIRUS)

ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented promising findings from a study…

Mar 17, 2025

ACTG PRESENTS FOUR STUDIES AT CROI DESCRIBING FINDINGS FROM SLIM LIVER

Presentations highlight relationship between semaglutide and blood markers of gene modification age predictors, gut bacteria, heart and metabolic effects, and…

Mar 17, 2025

ACTG ANNOUNCES PUBLICATION OF BEE-HIVE TRIAL IN JAMA

Dec 04, 2024

ACTG PRESENTS DATA ANALYSIS AT AIDS 2024 SHOWING ASSOCIATION BETWEEN ELEVATED RISK OF CARDIOVASCULAR EVENTS AND ABACAVIR USE AMONG PEOPLE LIVING WITH HIV

Jul 23, 2024

A5128: Plan for Obtaining Informed Consent to use Stored Human Biological Materials (HBM) for Currently Unspecified Analysis.

Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…

temporary-closed

Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis

See locations

A5243: Non-US Genomic Sampling

Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…

Closed to accrual

Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis

See locations

A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO)

You are being asked to take part in this research study because you are infected with HIV, the virus that…

Closed to accrual

HIV comorbidities and complications

Participants will be followed for 366 weeks (7 years).

See locations